toggle

efpia

Pharmaceutical industry research and development in europe

All new medicines introduced into the market are the result of lengthy, costly and risky research and development conducted by pharmaceutical companies:

  • 12 to 13 years

    Average time for a medicinal product to reach the market, since the first synthesis of the new active substance.

  • 1172 million

    The estimated cost of researching and developing a new chemical or biological entity in 2012.

    ($1506 million in 2011)

    (Mestre-ferrandiz et al, office of Health Economics, December 2012)

  • 2 out of 10 000

    Average substances in laboratories that will successfully pass all stages of development required to become a marketable medicine

Causes of death by major disease areas in europe

Data source: Eurostat, data relate to year 2010 (non-disease directly related causes of deaths: EFPIA calculations – percentages do not add due to rounding), April 2014

  • Diseases of the circulatory system
  • Malignant neoplasms
  • Diseases of the respiratory system
  • Diseases of the digestive system
  • Diseases of the nervous system and the sense organs
  • Endocrine, nutritional and metabolic diseases
  • Mental and behavioural disorders
  • Diseases of the genitourinary system
  • Certain infectious and parasitic
  • Diseases of the musculoskeletal system and connective tissues
  • Diseases of the blood(-forming organs) and immune mechanism disorders
  • Diseases of the skin and subcutaneous tissue
  • Others (Non-disease related causes of deaths)
close